AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: LINZESS (AbbVie and Ironwood Pharmaceuticals) (linzess.com)
A professionally clinical and highly compliant site that provides significant substance over signal. Its BS score is almost exclusively derived from the use of stale 2020 market data to support 2026 leadership claims and a technical lack of outbound proof verification links. It is a textbook example of high-substance pharma marketing that suffers from ‘data legacy’ issues.
Update the IQVIA and Kantar tracking data to 2024 or 2025 results to validate current market leadership claims. Replace the stale 2022 insurance cost design information with 2025/2026 data. Fix the technical heading hierarchy where H3 tags are being used as empty containers for video transcripts. Include sameAs links in the schema for featured experts like Dr. Susan Lucak to bridge the authority gap.
Information density is exceptionally high due to the presence of technical drug specifications like 72 mcg, 145 mcg, and 290 mcg dosages and the mechanism of action as a guanylate cyclase-C agonist. Headings are functional rather than fluff-heavy, focusing on Symptoms, Uses, and Financial Support. There is minimal use of generic power words, though there is significant repetition of the $30 savings claim across all four pages. The text-to-substance ratio is favorable, with body content delivering specific clinical expectations such as constipation relief typically felt in about 1 week.
A validator checks markup; an AI audit checks comprehension. Start your free one page AI interpretation to see how your structured data is actually interpreted by LLMs.
There is virtually zero semantic drift between the homepage signal and sub-page substance. The homepage H1 ‘Get Ahead of Your Returning IBS‑C Symptoms’ is supported by granular definitions of IBS-C versus CIC on the ‘Understanding Constipation’ page and efficacy timelines on the ‘Why LINZESS’ page. The messaging regarding eligibility for savings remains consistent from the homepage teaser to the detailed Program Terms on the ‘Savings and Support’ page. No contradictions were found in target audience or service level across the four crawled URLs.
Move beyond vague agency reporting and visualize your surgical implementation plan. Order an Executive SEO Strategy and stop relying on superficial keyword tracking.
The site triggers a trust theatre penalty because the metadata reports a proof_links_count of 0 despite making several bold market claims, such as being the #1 Prescribed Branded Treatment. Furthermore, the statistics cited (Kantar 2020 study and IQVIA 2020 data) are significantly stale, being over 60 months old relative to the current May 2026 anchor date. While the site provides transcripts for patient videos and discloses ‘Actor Portrayal,’ the lack of verified outbound proof links to the raw data sources in the metadata suggests a reliance on internal trust-building mechanisms.
Specific proof points are abundant, including the exact number of estimated sufferers (11.5 million for IBS-C and 28.5 million for CIC) and specific out-of-pocket cost percentages (92% of prescriptions between $0-$50). Verifiable evidence outweighs vague assertions by a significant margin. The primary density failure is the reliance on 2020-2022 data in a 2026 context, reducing the credibility of the ‘Number 1’ status.
To review a full competitive diagnostic applied to an enterprise level technical SEO agency, including a direct comparison against Dejan, examine the complete executive audit. View the iPullRank Executive SEO Strategy Dashboard for a practical example of how perception gaps, value prop drift, and audience misalignment are surfaced in real audits.
The site follows a rigid pharmaceutical template fingerprint including ‘For Healthcare Professionals,’ ‘Patient Resources,’ and the ubiquitous bottom-scrolling safety information. The value proposition is product-specific (linaclotide) and cannot be easily copy-pasted onto a competitor without changing the entire clinical profile. However, it uses common industry cliches like ‘real people’ and ‘talk to your doctor’ which, while medically necessary, are standard template language for the category. boiler-plate ‘You are now leaving’ modals are found on every page.
Authority is well-established through the AbbVie and Ironwood corporate entities, supported by detailed MedicalCondition and MedicalTherapy schema. A minor gap exists where Dr. Susan Lucak is named as an expert but is not connected to a digital footprint or Person schema within the provided structured data. Technical implementation is clean, though several H3 tags appear to be empty or used solely for transcript toggles, which is a minor structural flaw.
The performance claims are remarkably grounded; the site avoids ‘cure’ language and instead uses ‘proactively manage.’ The claim of relief in ‘about 1 week’ is a specific, measurable timeline that is consistently caveated. The disconnect is primarily temporal; claiming market leadership in 2026 based on 2020 IQVIA data is a marketing stretch that lacks contemporary substantiation.
Medical Devices, Pharma & Biotech BS: LINZESS (AbbVie and Ironwood Pharmaceuticals) (linzess.com)
The site is a highly compliant pharmaceutical product website for LINZESS (linaclotide). It adheres strictly to FDA-mandated structures, including Boxed Warnings and Important Risk Information (IRI) sections.
If your entity graph is unstable, every other part of the framework inherits that instability. Study the Structured Data Framework Guide and see why schema is not markup — it is the machine readable definition of your domain.
“The score of 21 is driven primarily by the Trust and Proof pillar (8/20) due to stale evidence and missing verified proof paths in metadata. Commodity Fingerprint (4/15) also contributed due to the heavy reliance on industry-standard pharma templates. Information Density remains low (5/30) because the site provides specific medical and financial data rather than marketing fluff.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 30, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at LINZESS (AbbVie and Ironwood Pharmaceuticals) to view the most current version of their content and see directly what the company offers.